Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apratastat
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apratastat is an orally active, small molecule inhibitor that targets both tumor necrosis factor-alpha converting enzyme (TACE, also known as ADAM17) and matrix metalloproteinases (MMPs), particularly MMP13. It acts as a reversible dual inhibitor, blocking the release of TNF-alpha by inhibiting its conversion from membrane-bound to soluble form. Apratastat was developed for the treatment of inflammatory diseases such as rheumatoid arthritis and was investigated in phase II clinical trials. Despite demonstrating potent inhibition of TNF-alpha release in vitro, ex vivo, and in vivo studies, clinical development was terminated due to lack of efficacy in rheumatoid arthritis[1][4][6][7].
- Other names
- apratastat
02
Targets
ADAM17 (A disintegrin and metalloprotease 17)MMP13 (Matrix metalloproteinase-13)
Beyond the preview
Go deeper on apratastat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apratastat.